Click on image to view larger version.

Figure 1 Serum IGF-I (upper panel) and IGFBP-1 (lower panel) levels at baseline and at two and five years after randomization in the two study groups (circles = placebo group; squares = bezafibrate group). Data are presented as the least squares mean value ± SEM. Data were analyzed by two-way repeated measures analysis of variance (IGF-I: group p = 0.03, time p = 0.01, interaction p = 0.18; IGFBP-1: group p = 0.0005, time p = 0.91, interaction p = 0.90). *p < 0.05, **p < 0.01 between the two study groups (post-hoc Tukey-Kramer test).